Revenue growth rates may determine whether Palantir can sustain its current valuations in the long term.

Oscar Health stock (NYSE: OSCR) has recently increased to over $16 after reports of a possible two-year extension of Obamacare subsidies, which may positively influence demand for health insurance via ...

Tesla remains a Sell due to an unsustainable, overinflated valuation with a P/E of 322.44 and weak recent growth metrics. Q3 earnings showed record revenue and energy storage growth, but automotive ...

Lululemon's growth story isn't as smooth as it once was, but the stock now trades at a valuation that seemed impossible just a few years ago. Today, that narrative looks very different. After several ...

CoreWeave's third-quarter revenue more than doubled year-over-year. The AI infrastructure provider lowered the top end of its full-year revenue guidance range. The stock's valuation leaves little room ...